English
Suomi

Karin Wingstrand appointed member of the Board of Directors of Histolab Products AB

Press Release 15.5.2019

On 9 May 2019, Karin Wingstrand joined the Board of Directors of Histolab Products AB, a wholly-owned subsidiary of the Algol Group. Karin qualified as a pharmacist from the University of Uppsala in 1982. She has a background in AstraZeneca, where she has held several senior positions in various R&D units.

Currently, Karin Wingstrand is active as a Board member and advisor in a number of private and listed companies as well as organisations in the healthcare and medical technology sector.

"I have a very positive impression of Histolab as a company, and I look forward to contributing to its continued development", she comments her appointment to the Board.

"Karin's industry experience and leadership perspective will be a great asset to our Board, and I am very pleased to welcome her to the company", says Alexander Bargum, Algol Group CEO and Chairman of the Board of Histolab.

The other Board members in Histolab are Managing Director Olof Jenefeldt and Jan Salomonson, who has served on the Board as an independent Director since 2000.

Additional information

Alexander Bargum, Group CEO, +358 40 732 3232 (alexander.bargum@algol.fi).

Histolab in brief

Histolab, founded in 1965, is the leading provider of comprehensive solutions for research and clinical laboratories in cell diagnostics in Sweden and Europe. The company offers a wide range of instruments, consumables, chemicals, antibodies, reagents and storage. The products are used daily by laboratories, researchers and hospital staff who see reliable test results as a matter of course in their work. Histolab is the parent company of Histocenter, a leading histotechnology specialist.

Both Histolab and Histocenter are part of the Algol Group, a Finnish multi-industry group in the field of trade and services. We operate responsibly and with 125 years of experience in a broad international network of partners. Our solutions improve the quality and ensure the flow in manufacturing processes. In the healthcare sector, we contribute to the basis for a better life. The Algol Group had net sales of 178 million euros in 2018. We employ 450 professionals in ten countries.  www.algol.fi